NEW YORK – Johnson & Johnson said Wednesday that it is reorganizing its consumer business, including giving more attention to its McNeil Consumer Healthcare unit, which has been stung by about 20 recalls of popular over-the-counter products such as Tylenol, Motrin, Rolaids and Benadryl.
The company said the consumer businesses will be organized into North America, Latin America, Asia-Pacific, and Europe-Middle East-Africa. The changes will take effect April 4.
The U.S. over-the-counter drug business will constitute yet another organization so that Johnson & Johnson can focus on McNeil, which had been part of a larger group of consumer health care units.
Johnson & Johnson said the changes will allow it to “give focused attention to quality and compliance, and the critical task of restoring McNeil Consumer Healthcare brands.”
The New Brunswick, N.J., company said Pat Mutchler will be in charge of the McNeil business. He will also lead other division and the company’s joint venture with Merck & Co.
Millions of bottles of McNeil products have been recalled since September 2009. The New Brunswick, N.J., company said those problems cost it $900 million in sales in 2010.
Send questions/comments to the editors.
Success. Please wait for the page to reload. If the page does not reload within 5 seconds, please refresh the page.
Enter your email and password to access comments.
Hi, to comment on stories you must . This profile is in addition to your subscription and website login.
Already have a commenting profile? .
Invalid username/password.
Please check your email to confirm and complete your registration.
Only subscribers are eligible to post comments. Please subscribe or login first for digital access. Here’s why.
Use the form below to reset your password. When you've submitted your account email, we will send an email with a reset code.